The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients.
In the general population, elevated cholesterol is associated with cardiovascular disease and mortality and lowering cholesterol is associated with improved outcomes. This reflects the predominance of isolated atherosclerotic coronary disease in the general population. In patients with renal disease, however, the relationship between serum lipids and cardiovascular outcomes is much less clear and even reversed. In our opinion, the relationship between cholesterol and coronary disease is obscured by high levels of co-morbid disease, malnutrition, inflammation, atypical dyslipidemia and the fact that myocardial infarction is not the typical presentation of cardiovascular disease in patients with renal disease. Thus, cholesterol lowering will still be effective in patients with chronic kidney diseases.
Wan
Ray K
RK
BHF Cardiovascular Research Centre, University of Glasgow, and Renal Transplant Unit, Western Infirmary, Glasgow, United Kingdom.
Mark
Patrick B
PB
Jardine
Alan G
AG
D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D007249:Inflammation / Q000150:complications; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D044342:Malnutrition / Q000150:complications; D008955:Models, Cardiovascular; D006435:Renal Dialysis; D012307:Risk Factors
D002784:Cholesterol